Geriatric Research Education and Clinical Center, Durham VA Medical Center, 508 Fulton St. (119), Durham, NC 27705, USA.
Int Urol Nephrol. 2012 Dec;44(6):1649-56. doi: 10.1007/s11255-012-0275-0. Epub 2012 Sep 16.
Lower urinary tract symptoms (LUTS) affect countless individuals worldwide with an increased prevalence among those≥60 years of age. As the world's population ages, the prevalence of LUTS will continue to increase, diminishing the quality of life of many men and women. For men, alpha-1-adrenergic receptor (α1-AR) blockers are used as first-line therapy to mitigate bothersome LUTS, but for women with LUTS, few treatments have been adequately studied. However, new research has emerged evaluating the use of tamsulosin and other α1-AR blockers in female LUTS. Thus, the purpose of this review is to evaluate clinical trials using tamsulosin for the treatment of LUTS in women to determine if tamsulosin is an appropriate treatment option.
A comprehensive search of the MEDLINE (1966-May 2012) and EMBASE (1980-May 2012) databases was performed. Additional articles were retrieved by manual review of the references cited in publications from the database search. Five published clinical trials and two abstracts were identified.
All seven trials presented in this review demonstrated statistically significant primary outcomes with use of tamsulosin in female LUTS, especially in women with predominant voiding dysfunction. Such efficacy measures included a reduction in urinary symptoms as well as improvements in quality of life and sleep quality. Tamsulosin was found to be safe and well tolerated in all studies reviewed.
Consistent positive findings across multiple clinical studies suggest that in women with LUTS, particularly those with voiding dysfunction, tamsulosin may be an effective and safe treatment option.
下尿路症状（LUTS）影响着全球无数人，在 60 岁以上人群中的发病率更高。随着世界人口老龄化，LUTS 的发病率将继续增加，降低许多男性和女性的生活质量。对于男性，α1-肾上腺素能受体（α1-AR）阻滞剂被用作缓解烦扰性 LUTS 的一线治疗药物，但对于 LUTS 女性患者，很少有治疗方法得到充分研究。然而，新的研究已经出现，评估了坦索罗辛和其他α1-AR 阻滞剂在女性 LUTS 中的应用。因此，本综述的目的是评估使用坦索罗辛治疗女性 LUTS 的临床试验，以确定坦索罗辛是否是一种合适的治疗选择。
对 MEDLINE（1966 年-2012 年 5 月）和 EMBASE（1980 年-2012 年 5 月）数据库进行全面检索。通过手动查阅数据库检索出版物中的参考文献，获取了其他文章。共确定了 5 项已发表的临床试验和 2 项摘要。
本综述中介绍的所有 7 项试验均表明坦索罗辛在女性 LUTS 中的使用具有统计学显著的主要结局，特别是在以排尿功能障碍为主的女性中。这些疗效指标包括尿症状的减少以及生活质量和睡眠质量的改善。在所有回顾的研究中，坦索罗辛均被发现安全且耐受良好。
多项临床研究的一致积极结果表明，在女性 LUTS 患者中，尤其是那些有排尿功能障碍的患者，坦索罗辛可能是一种有效且安全的治疗选择。
